Acceso rápido

No sigues ninguna revista

Explorar revistas

No hay artículos guardados

Explorar artículos

Política de privacidad

Feed Explorar shellTopNav.journalClub Tendencias Preguntas Investigadores

⌘K

Trial shows safety of switch to xanomeline‐trospium combination in stable patients | Synapse

April 10, 2026

Trial shows safety of switch to xanomeline‐trospium combination in stable patients

Puntos clave

To evaluate the safety and effectiveness of switching stable schizophrenia patients to xanomeline-trospium combination therapy.
Conducted a 52-week open-label trial
Participants were psychiatrically stable adults with schizophrenia
Switched from prior antipsychotics to xanomeline and trospium chloride
No new safety issues were identified during the trial
Improvements observed in schizophrenia symptom severity measures

Resumen

Psychiatrically stable adults with schizophrenia were safely switched from their prior antipsychotic to the combination of xanomeline and trospium chloride, with no new safety issues uncovered, a 52‐week open‐label trial has found. The drug combination also led to improvements on measures of schizophrenia symptom severity. Results of the study were published online Jan. 7, 2026, in Schizophrenia Research .

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Loading...

Cite this study

A Wed, study studied this question.

www.synapsesocial.com/papers/69d896046c1944d70ce072f1 — DOI: https://doi.org/10.1002/pu.31438

Journals

The Brown University Psychopharmacology Update

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Loading...